Last week’s news that J&J is abandoning their coronary stent business was sad, but provided several lessons about poor product development execution and the need for constant innovation. J&J created ...

Johnson & Johnson's (JNJ) announcement that it is getting out of the drug-eluting stent business-- those are the tiny drug-covered tubes inserted into arteries to prevent strokes -- was blamed by many ...

Johnson & Johnson may have a better product than its rival, Boston Scientific, for holding open clogged arteries. New data published in the two leading medical journals indicates that patients who ...

Johnson & Johnson said late Thursday it plans to buy Conor Medsystems for $1.4 billion in cash, a bid by the pharmaceuticals giant to expand its presence in the $6 billion-a-year market for ...

NEW YORK, May 19 (Reuters) - Johnson & Johnson said six-month study data showed its new experimental stent was better than Boston Scientific's Taxus at preventing re-growth of tissue within the tiny ...

Johnson & Johnson will stop selling drug-coated heart stents, a former profit driver for the diversified healthcare company that has stumbled due to safety concerns and fierce competition from rival ...

The therapy of deep infiltrating endometriosis places the highest demands. Double-J (DJ) stent insertion is recommended preoperatively. However, we could not find any publication in PubMed that showed ...

Apparently, Johnson & Johnson didn't want to wait and see what the FDA's expert advisors think of Abbott Laboratories' Xience stent. The company filed suit against Abbott for patent infringement ...

CHICAGO — Researchers reported Tuesday that an antibiotic-coated stent developed by Johnson & Johnson to prop open clogged arteries completely prevented reclogging during a seven-month period, and ...

Are you an aspiring producer who has a fresh take on music and an ear for an authentic sound? Then you could be one of a few who might be chosen to remix veteran musician Mark Stent’s new album.